Furthermore, in the context of immunotherapy, VEGF-C exerted anti-tumor effects through the infiltration of CCR7+ immune cells, enhancing the therapeutic efficacy of anti-PD-1 on HCC models. The gene discussed is CCR7; the disease is hepatocellular carcinoma.